AAV Vector Resource
AAV packaging quality control must go beyond vector titer to confirm that each production lot contains intact, functional, and sufficiently pure vector. A robust assessment combines genome integrity, full/empty/partial capsid distribution, residual DNA and protein, endotoxin, transduction activity, and stability testing to identify packaging or purification problems before use. Together, these orthogonal assays support reliable dose interpretation, lot consistency, and suitability for research or translational studies.
Direct Answer
The inner ear is anatomically compact but cell-rich. Inner and outer hair cells, supporting cells, and spiral ganglion neurons sit at different positions and have distinct biology, so the first decision is which cell type you actually need to transduce.
Promoters are not "absolutely specific"—their expression range shifts with species, age, cochlear region, capsid, and delivery method. High-specificity studies should combine literature evidence with experimental validation.
The key principle: otic AAV is a combination of capsid, promoter, and delivery route—not a serotype chosen in isolation.
Hair cells are the primary sensory target for hearing restoration; hair-cell-related promoters drive expression in the sensory epithelium.
Supporting cells are studied for regeneration and structural support; supporting-cell-related regulatory elements are used.
Spiral ganglion neurons require neuronal regulatory elements and a delivery route that reaches the ganglion.
Selection Mapping
Start with the exact cochlear cell population and experimental endpoint, then select a capsid, promoter, and delivery route as one testable combination. Published tropism can shift with species, developmental stage, dose, and route; use matched reporter studies to map transduction across the apex, middle turn, and base before committing to an efficacy vector.
| Target Cell | Representative Promoter | Cochlear Region | Key Caveat |
|---|---|---|---|
| Inner / outer hair cells | Hair-cell-enriched regulatory elements; compare with a broad promoter in a reporter pilot | Inner and outer hair cells across apical, middle, and basal turns | Quantify inner versus outer hair-cell labeling separately; check off-target expression and hearing-related tolerability at the planned route and dose |
| Supporting cells | Supporting-cell-associated regulatory elements; verify expression against hair-cell markers | Supporting-cell subtypes within the sensory epithelium | Capsid entry and promoter restriction are separate variables; report transduced supporting-cell fraction and expression outside the intended population |
| Spiral ganglion neurons | Neuronal promoter or enhancer suited to the selected ganglion population | Spiral ganglion along the cochlear turns, including neuronal somata | Assess whether the route reaches the ganglion and quantify neuronal versus non-neuronal expression; hair-cell tropism does not establish ganglion delivery |
For cell-type-restricted expression, explore specific promoter-driven AAV targeting and tissue/cell-specific AAV vector services.
Design Logic
Working from the research goal outward—rather than from the serotype inward—keeps each variable aligned with the next, ending in functional hearing readouts.
Genetic deafness, hair-cell injury, regeneration, or auditory function?
Hair cell, supporting cell, or spiral ganglion neuron.
Match the regulatory element to the cell and expression need.
Combine serotype with model, region, and published data.
Round window membrane or intracochlear injection.
Key Variables
Several interacting variables determine whether your AAV reaches and labels the right cochlear cells. Controlling them turns a theoretical vector into a reproducible result.
No promoter is absolutely specific; verify the expression range with a reporter in your model and species.
Cochlear cell tropism differs by serotype and route—validate rather than extrapolate from literature.
Round window and intracochlear routes reach different cochlear regions; surgical access and anatomy matter.
AAV is limited to ~4.7 kb; account for promoter, tag, and reporter when sizing the insert.
scAAV accelerates onset but halves capacity—useful for fast reporter expression.
Pair expression data with auditory brainstem response (ABR) and histology to confirm functional outcome.
Delivery Routes
There is no single "best" route. The right choice depends on which cochlear cells are targeted, the desired coverage, and the animal model.
For localized inner-ear access: a common route that relies on diffusion into the cochlea, with distribution affected by capsid and dose.
For more defined local delivery: places the vector directly in the cochlea but requires more invasive surgery and attention to tissue trauma.
Confirm expression: regardless of route, verify distribution, target-cell transduction, and functional outcome before scaling up.
From Question to Evidence
Creative Biolabs can design, construct, and package the AAV that matches your otic target, from capsid selection through production and titration.
Define the intended cochlear cell population and compare promoter, capsid, and cassette options within the available AAV cargo capacity. Build a reporter or study-specific construct with expression elements selected for the model, route, and readout before advancing a lead design.
Screen engineered or modified capsids for access to the intended hair cells, supporting cells, or spiral ganglion neurons under the planned delivery conditions. Compare target-cell coverage and off-target labeling with a reference capsid, then carry forward variants that fit the study goal.
Produce and purify the selected capsid–cassette combination at a concentration suited to the planned local administration volume. Align lot size, formulation, and handling with the study schedule, and review titer, identity, and purity before material is assigned to cohorts.
Measure genome titer with a defined qPCR or ddPCR target and use a relevant cell-based transduction readout when functional activity matters. Record vg per ear, delivered volume, and assay conditions so comparisons between capsids, ears, and production lots remain interpretable.
Review available recombinant AAV products for compatible targets and expression cassettes when a standard construct fits the experiment. Confirm the product capsid, promoter, genome design, and supplied quality data against the intended cell population and delivery route.
Selected Reading
Landegger LD, Pan B, Askew C, et al. A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear. Nat Biotechnol. 2017;35(3):280-284. https://doi.org/10.1038/nbt.3781.
Akil O, Dyka F, Calvet C, et al. Dual AAV-mediated gene therapy restores hearing in a mouse model of Usher syndrome type 1c. Nat Biotechnol. 2019;37(5):538-547. https://doi.org/10.1038/s41587-019-0082-6.
Isgrig K, McDougald DS, Zhu J, et al. AAV2.7m8 is a powerful viral vector for inner ear gene therapy. Nat Commun. 2019;10(1):427. https://doi.org/10.1038/s41467-018-08243-1.
FAQ
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
